Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.
Guilherme Sacchi de Camargo Correia, MD
Advertisement
Articles by Guilherme Sacchi de Camargo Correia, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Durvalumab/Carboplatin/Etoposide Prove Tolerable in ES-SCLC
2
Tarlatamab Earns Traditional FDA Approval in ES-SCLC
3
FDA Approves Sevabertinib in Non-Squamous NSCLC
4
FDA Accepts NDA for Zidesamtinib in Pretreated Advanced ROS1+ NSCLC
5
